SCHEMBL3557570

SCHEMBL3557570

CC(C)(C)OC(=O)NCc1ccc(C(=O)Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.55
GAA P10253 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.52
HDAC1 Q13547 3/20 0.51
HDAC6 Q9UBN7 3/20 0.49
HDAC10 Q969S8 1/20 0.49
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPT P10636 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
RECQL P46063 1/20 0.44
KDM4A O75164 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPN P05981 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3180689 0.88 L3MBTL1 (0.61) NAMPTGAAL3MBTL1HDAC1HDAC6
SCHEMBL8127981 0.86 EPHX2 (0.59) NAMPTGAAL3MBTL1HDAC1HDAC6
SCHEMBL133327 0.86 KMT2A (0.60) NAMPTGAAL3MBTL1HDAC1CA1
SCHEMBL10165179 0.86 NAMPT (0.56) NAMPTGAAL3MBTL1HDAC1HDAC6
SCHEMBL8276814 0.85 ALDH1A1 (0.63) NAMPTGAAL3MBTL1HDAC1HDAC6
SCHEMBL8337876 0.85 NAMPT (0.53) NAMPTGAAL3MBTL1HDAC1HDAC6
SCHEMBL8220824 0.84 EPHX2 (0.60) NAMPTGAAL3MBTL1HDAC1HDAC6
SCHEMBL21119732 0.84 NAMPT (0.55) NAMPTGAAL3MBTL1HDAC1HDAC6
SCHEMBL1206337 0.84 NAMPT (0.55) NAMPTGAAL3MBTL1HDAC1CA1
SCHEMBL6347286 0.84 GAA (0.72) NAMPTGAAL3MBTL1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240270762-A1 PENICILLIN-BINDING PROTEIN INHIBITORS SPRING MILL PHARMA, INC. 2024-08-15 US disclosed
US-20220387615-A1 COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF DANMARKS TEKNISKE UNIVERSITET (DK) 2022-12-08 US disclosed
EP-3990027-A1 COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF Danmarks Tekniske Universitet (DK) 2022-05-04 EP disclosed
US-20100267779-A1 Novel Compounds and Methods of Using Them SYNDAX PHARMACEUTICALS, INC. (US) 2010-10-21 US disclosed
US-20100267779-A1 Novel Compounds and Methods of Using Them SYNDAX PHARMACEUTICALS, INC. (US) 2010-10-21 US disclosed
US-7678787-B2 Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists WYETH (US) 2010-03-16 US disclosed
WO-2009015237-A1 NOVEL COMPOUNDS AND METHODS OF USING THEM SYNDAX PHARMACEUTICALS, INC. (US) 2009-01-29 WO disclosed
EP-1893615-A1 PYRROLOBENZODIAZEPINE PYRIDINE CARBOXAMIDES AND DERIVATIVES AS FOLLICLE-STIMULATING HORMONE RECEPTOR ANTAGONISTS Wyeth a Corporation of the State of Delaware (US) 2008-03-05 EP disclosed
US-20060287522-A1 Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists WYETH (US) 2006-12-21 US disclosed
WO-2006135687-A1 PYRROLOBENZODIAZEPINE PYRIDINE CARBOXAMIDES AND DERIVATIVES AS FOLLICLE-STIMULATING HORMONE RECEPTOR ANTAGONISTS WYETH (US) 2006-12-21 WO disclosed
EP-0767794-B1 PHOSPHINIC ACID DERIVATIVES SCHERING CORP (US) 2000-02-02 EP disclosed
WO-1996000732-A9 PHOSPHINIC ACID DERIVATIVES 1996-02-22 WO disclosed
US-5476847-A Treating cardiovascular, gastrointestinal, urogenital disorders SCHERING CORPORATION (US) 1995-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267779-A1 Novel Compounds and Methods of Using Them HDAC1, HDAC3, HDAC6 NAMPT 282/4885GAA 79/4885L3MBTL1 2128/4885
US-20220387615-A1 COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF ADAM17, ADAM8, ADAM33 NAMPT 985/4885GAA 83/4885L3MBTL1 2853/4885
US-20060287522-A1 Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists FSHR, GNRHR, PRLHR NAMPT 1960/4885GAA 4783/4885L3MBTL1 4883/4885
US-20240270762-A1 PENICILLIN-BINDING PROTEIN INHIBITORS PEPD, BPGM, EBPL NAMPT 828/4885GAA 345/4885L3MBTL1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.